Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Par…

Hereditary Spastic Paraplegia Type 50

~Estimated

~$10 – $8,750

Elpida Therapeutics SPCNCT06692712

Phase 1

Safety and Efficacy of AAV9/AP4B1 For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration

Safety and Efficacy of AAV9/AP4B1 For Patients with AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of…

HSPHereditary Spastic ParaplegiaHereditary Spastic Paraparesis+10 more

~Estimated

~$10 – $8,750

BlackfinBio LtdNCT06948019